For research use only. Not for therapeutic Use.
Ropinirole Hydrochloride is a dopamine receptor agonist, selective for the D2DR, D3DR (D2 and D3 receptors). It is primarily used to treat Parkinson/’s disease and restless legs syndrome.
| Catalog Number | I009184 |
| CAS Number | 91374-20-8 (HCl) |
| Synonyms | Ropinirole Hydrochloride; Ropinirole HCl; UNII-D7ZD41RZI9; SK and F 101468; SK and F-101,468; SKF 101468; SmithKline Beecham brand of ropinirole hydrochloride;;4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride |
| Molecular Formula | C16H25ClN2O |
| Purity | ≥95% |
| Target | Dopamine Receptor Agonist |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | 4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one;hydrochloride |
| InChI | InChI=1S/C16H24N2O.ClH/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15;/h5-7H,3-4,8-12H2,1-2H3,(H,17,19);1H |
| InChIKey | XDXHAEQXIBQUEZ-UHFFFAOYSA-N |
| SMILES | CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1.Cl |
| Reference | </br>1:Development of smart hydrogels of etherified gum ghatti for sustained oral delivery of Ropinirole Hydrochloride. Ray S, Roy G, Maiti S, Bhattacharyya UK, Sil A, Mitra R.Int J Biol Macromol. 2017 Apr 27. pii: S0141-8130(17)30026-0. doi: 10.1016/j.ijbiomac.2017.04.059. [Epub ahead of print] No abstract available. PMID: 28457956 </br>2:Ex vivo buccal drug delivery of ropinirole hydrochloride in the presence of permeation enhancers: the effect of charge. Kontogiannidou E, Andreadis DA, Zografos AL, Nazar H, Klepetsanis P, van der Merwe SM, Fatouros DG.Pharm Dev Technol. 2016 Jan 21:1-5. [Epub ahead of print] PMID: 26794504 </br>3:PLGA/DPPC/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment. Karavasili C, Bouropoulos N, Sygellou L, Amanatiadou EP, Vizirianakis IS, Fatouros DG.Mater Sci Eng C Mater Biol Appl. 2016 Feb;59:1053-62. doi: 10.1016/j.msec.2015.11.028. Epub 2015 Nov 11. PMID: 26652464 </br>4:The development of a short route to the API ropinirole hydrochloride. Yousuf Z, Richards AK, Dwyer AN, Linclau B, Harrowven DC.Org Biomol Chem. 2015 Nov 14;13(42):10532-9. doi: 10.1039/c5ob01739d. Epub 2015 Sep 4. PMID: 26337252 </br>5:Controlled release of ropinirole hydrochloride from a multiple barrier layer tablet dosage form: effect of polymer type on pharmacokinetics and IVIVC. Malewar N, Avachat M, Pokharkar V, Kulkarni S.AAPS PharmSciTech. 2013 Sep;14(3):1178-89. doi: 10.1208/s12249-013-0009-3. Epub 2013 Jul 30. PMID: 23897037 Free PMC Article</br>6:Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ.J Mater Sci Mater Med. 2013 Sep;24(9):2101-15. doi: 10.1007/s10856-013-4965-7. Epub 2013 Jun 1. PMID: 23728521 </br>7:Fabrication and statistical optimization of surface engineered PLGA nanoparticles for naso-brain delivery of ropinirole hydrochloride: in-vitro-ex-vivo studies. Patil GB, Surana SJ.J Biomater Sci Polym Ed. 2013;24(15):1740-56. doi: 10.1080/09205063.2013.798880. Epub 2013 May 24. PMID: 23705812 </br>8:Formulation and optimization of ethosomes for transdermal delivery of ropinirole hydrochloride. Mishra AD, Patel CN, Shah DR.Curr Drug Deliv. 2013 Oct;10(5):500-16. PMID: 23410071 </br>9:Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. Singh ND, Banga AK.J Drug Target. 2013 May;21(4):354-66. doi: 10.3109/1061186X.2012.757768. Epub 2013 Jan 11. PMID: 23311703 </br>10:Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR, Surana SJ.Drug Deliv. 2013;20(1):47-56. doi: 10.3109/10717544.2012.752421. PMID: 23311653 |
